1. bookVolume 67 (2017): Edizione 3 (September 2017)
Dettagli della rivista
License
Formato
Rivista
eISSN
1846-9558
Prima pubblicazione
28 Feb 2007
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Accesso libero

Influence of novel oral anticoagulants on anticoagulation care management

Pubblicato online: 30 Aug 2017
Volume & Edizione: Volume 67 (2017) - Edizione 3 (September 2017)
Pagine: 397 - 406
Accettato: 31 May 2017
Dettagli della rivista
License
Formato
Rivista
eISSN
1846-9558
Prima pubblicazione
28 Feb 2007
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese

1. W. Ageno, A. S. Gallus, A. Wittkowsky, M. Crowther, E. M. Hylek and G. Palareti, Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest141 (2012) e44S-88S; DOI: 10.1378/chest.11-2292.10.1378/chest.11-2292327805122315269Search in Google Scholar

2. A. Mavri and G. Tratar, Kakovost vodenja antikoagulacijskega zdravljenja v Sloveniji [Quality of the management of anticoagulant therapy in Slovenia], ISIS16 (2007) 56–59.Search in Google Scholar

3. A. J. Camm, G. Y. Lip, R. De Caterina, I. Savelieva, D. Atar, S. H. Hohnloser, G. Hindricks and P. Kirchhof, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur. Heart J.33 (2012) 2719–2747; DOI: 10.1093/eurheartj/ehs253.10.1093/eurheartj/ehs25322922413Search in Google Scholar

4. R. G. Hart, L. A. Pearce and M. I. Aguilar, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann. Intern. Med.146 (2007) 857–867; DOI: 10.7326/0003-4819-146-12-200706190-00007.10.7326/0003-4819-146-12-200706190-0000717577005Search in Google Scholar

5. S. J. Wilson, P. S. Wells, M. J. Kovacs, G. M. Lewis, J. Martin, E. Burton and D. R. Anderson, Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial, CMAJ169 (2003) 293–298.Search in Google Scholar

6. C. J. Heneghan, J. M. Garcia-Alamino, E. A. Spencer, A. M. Ward, R. Perera, C. Bankhead, P. Alonso-Coello, D. Fitzmaurice, K. R. Mahtani and I. J. Onakpoya, Self-monitoring and self-management of oral anticoagulation, Cochrane Database Syst. Rev.7 (2016) CD003839; DOI: 10.1002/14651858.CD003839.pub3.10.1002/14651858.CD003839.pub3807837827378324Search in Google Scholar

7. S. Testa, O. Paoletti, A. Zimmermann, L. Bassi, S. Zambelli and E. Cancellieri, The role of anticoagulation clinics in the era of new oral anticoagulants, Thrombosis2012 (2012) Article ID 835356, 6 pages; DOI: 10.1155/2012/835356.10.1155/2012/835356347776923097696Search in Google Scholar

8. G. D. Barnes, B. K. Nallamothu, A. E. Sales and J. B. Froehlich, Reimagining anticoagulation clinics in the era of direct oral anticoagulants, Circ. Cardiovasc. Qual. Outcomes9 (2016) 182–185; DOI: 10.1161/Circoutcomes.115.002366.10.1161/CIRCOUTCOMES.115.002366479435026933047Search in Google Scholar

9. A. Janzic and M. Kos, Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control, Pharmacoeconomics33 (2015) 395–408; DOI: 10.1007/s40273-014-0246-7.10.1007/s40273-014-0246-725512096Search in Google Scholar

10. N. L. Liberato and M. Marchetti, Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review, Expert Rev. Pharmacoecon. Outcomes Res.16 (2016) 221–235; DOI: 10.1586/14737167.2016.1147351.10.1586/14737167.2016.114735126817497Search in Google Scholar

11. R. E. Malmstrom, B. B. Godman, E. Diogene, C. Baumgartel, M. Bennie, I. Bishop, A. Brzezinska, A. Bucsics, S. Campbell, A. Ferrario, A. E. Finlayson, J. Furst, K. Garuoliene, M. Gomes, I. Gutierrez-Ibarluzea, A. Haycox, K. Hviding, H. Herholz, M. Hoffmann, S. Jan, J. Jones, R. Joppi, M. Kalaba, C. Kvalheim, O. Laius, I. Langner, J. Lonsdale, S. A. Loov, K. Malinowska, L. McCullagh, K. Paterson, V. Markovic-Pekovic, A. Martin, J. Piessnegger, G. Selke, C. Sermet, S. Simoens, C. Tulunay, D. Tomek, L. Voncina, V. Vlahovic-Palcevski, J. Wale, M. Wilcock, M. Wladysiuk, M. van Woerkom, C. Zara and L. L. Gustafsson, Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs, Front. Pharmacol.4 (2013) Article ID 39; DOI: 10.3389/fphar.2013.00039.10.3389/fphar.2013.00039365306523717279Search in Google Scholar

12. B. Godman, R. E. Malmstrom, E. Diogene, A. Gray, S. Jayathissa, A. Timoney, F. Acurcio, A. Alkan, A. Brzezinska, A. Bucsics, S. M. Campbell, J. Czeczot, W. de Bruyn, I. Eriksson, F. A. Yusof, A. E. Finlayson, J. Furst, K. Garuoliene, A. Guerra Junior, J. Gulbinovic, S. Jan, R. Joppi, M. Kalaba, E. Magnisson, L. McCullagh, K. Miikkulainen, G. Ofierska-Sujkowska, H. B. Pedersen, G. Selke, C. Sermet, S. Spillane, A. Supian, I. Truter, V. Vlahovic-Palcevski, L. E. Vien, E. H. Vural, J. Wale, M. Wladysiuk, W. Zeng and L. L. Gustafsson, Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?, Expert. Rev. Clin. Pharmacol.8 (2015) 77–94; DOI: 10.1586/17512433.2015.990380.10.1586/17512433.2015.99038025487078Search in Google Scholar

13. B. Godman, R. E. Malmstrom, E. Diogene, S. Jayathissa, S. McTaggart, T. Cars, S. Alvarez-Madrazo, C. Baumgartel, A. Brzezinska, A. Bucsics, S. Campbell, I. Eriksson, A. Finlayson, J. Furst, K. Garuoliene, I. Gutierrez-Ibarluzea, K. Hviding, H. Herholz, R. Joppi, M. Kalaba, O. Laius, K. Malinowska, H. B. Pedersen, V. Markovic-Pekovic, J. Piessnegger, G. Selke, C. Sermet, S. Spillane, D. Tomek, L. Voncina, V. Vlahovic-Palcevski, J. Wale, M. Wladysiuk, M. van Woerkom, C. Zara and L. L. Gustafsson, Dabigatran – a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs, Front. Pharmacol.5 (2014) Article ID 109; DOI: 10.3389/fphar.2014.00109.10.3389/fphar.2014.00109405053224959145Search in Google Scholar

14. T. Wilke, A. Groth, S. Mueller, M. Pfannkuche, F. Verheyen, R. Linder, U. Maywald, T. Kohlmann, Y. S. Feng, G. Breithardt and R. Bauersachs, Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients, Thromb. Haemost.107 (2012) 1053–1065; DOI: 10.1160/TH11-11-0768.10.1160/TH11-11-076822398417Search in Google Scholar

15. T. C. Sarich, J. H. Seltzer, S. D. Berkowitz, J. Costin, J. T. Curnutte, C. M. Gibson, M. Hoffman, E. Kaminskas, M. W. Krucoff, J. H. Levy, P. D. Mintz, P. A. Reilly, P. T. Sager, D. E. Singer, N. Stockbridge, J. I. Weitz and P. R. Kowey, Novel oral anticoagulants and reversal agents: Considerations for clinical development, Am. Heart J.169 (2015) 751–757; DOI: 10.1016/j.ahj.2015.03.010.10.1016/j.ahj.2015.03.01026027611Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo